Children’s Health Defense demands FDA withdraw its approval of Remdesivir for infants and children, citing 72% adverse events rate
Drug is highly toxic to adults; COVID poses virtually zero threat to this age group and unfinished drug trial reflects poor efficacy and safety evidence
News
•